NCT04615650

Brief Summary

Weight-bearing radiographs will be used to evaluate the stability of suprasyndesmotic ankle fractures. Patients with stable fractures will be randomised to operative or non-operative treatment.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

4 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 28, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 4, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

December 28, 2020

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

May 16, 2025

Status Verified

May 1, 2025

Enrollment Period

4.4 years

First QC Date

October 28, 2020

Last Update Submit

May 13, 2025

Conditions

Keywords

ankle fracturessurgical treatmentconservative treatmentweight-bearing

Outcome Measures

Primary Outcomes (1)

  • Olerud-Molander Ankle Score (OMAS)

    The primary outcome measure is the Olerud-Molander Ankle Score (OMAS), which is a condition-specific, patient-reported measure of ankle-fracture symptoms. OMAS ranges from 0 to 100, with higher scores indicating better outcomes and fewer symptoms.

    The main statistical analysis of the primary outcome will be based on the two-year follow-up.

Secondary Outcomes (6)

  • Ankle pain

    The main statistical analysis of the outcome will be based on the two-year follow-up.

  • Manchester-Oxford Foot Questionnaire (MOxFQ)

    The main statistical analysis of the outcome will be based on the two-year follow-up.

  • EuroQol questionnaire (EQ-5D)

    The main statistical analysis of the outcome will be based on the two-year follow-up.

  • Radiographic results

    The main statistical analysis of the outcome will be based on the two-year follow-up.

  • Range of motion

    The main statistical analysis of the outcome will be based on the two-year follow-up.

  • +1 more secondary outcomes

Study Arms (2)

Surgical treatment

ACTIVE COMPARATOR

Patients randomised to operative treatment will have their surgery performed by an orthopaedic surgeon or by orthopaedic trainees under the supervision of a consultant, when fit for surgery. The surgical technique and choice of implants will be decided by the surgeon in order to closely resemble everyday clinical practice. The syndesmosis must be reduced (closed or open) and fixed. Postoperatively, the patients will be treated with an ankle orthosis for six weeks with weight-bearing as tolerated.

Procedure: Surgical treatment

Non-surgical treatment

EXPERIMENTAL

Patients randomised to non-operative treatment are treated with an ankle orthosis for six weeks with weight-bearing as tolerated. Other types of casts can be used if preferred by the treating orthopaedic surgeon, but the cast must allow full weight-bearing and must prevent equinus position.

Device: Ankle orthosis

Interventions

Surgical treatment of suprasyndesmotic ankle fractures

Surgical treatment

Non-surgical treatment of suprasyndesmotic ankle fractures

Non-surgical treatment

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients who present with a closed, isolated fibular fracture classified as suprasyndesmotic (Weber C) with a medial clear space of less than 7 mm in mortise view on primary radiographs.
  • presentation less than 14 days after the injury.

You may not qualify if:

  • previous fractures or ligamentous injury to the injured ankle.
  • pathological fracture.
  • diabetic neuropathy or other neuropathies.
  • drug abuse.
  • inability to consent and/or comply.
  • inability to understand Norwegian language.
  • inability to walk unaided prior to the fracture.
  • patients with a concomitant tibial fracture requiring surgical treatment are excluded, but patients with undisplaced concomitant tibial fractures can be included.
  • patients from outside the catchment area of the recruiting hospitals. However, they can be included if they are willing to undergo follow-up visits at one of the recruiting hospitals.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Vestre Viken Hospital Trust

Bærums verk, Akershus, 1347, Norway

Location

Østfold Hospital Trust

Fredrikstad, Akershus, 1714, Norway

Location

Sykehuset Innlandet HF

Gjøvik, Innlandet, 2819, Norway

Location

Oslo University Hospital

Oslo, Oslo County, 4950, Norway

Location

Related Publications (1)

  • Saatvedt O, Riiser M, Frihagen F, Figved W, Madsen JE, Molund M, Furunes H. Non-operative versus operative treatment of suprasyndesmotic ankle fractures: protocol for a prospective, multicentre, randomised controlled trial. BMJ Open. 2024 Jan 8;14(1):e075122. doi: 10.1136/bmjopen-2023-075122.

MeSH Terms

Conditions

Ankle Fractures

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Fractures, BoneWounds and InjuriesAnkle InjuriesLeg Injuries

Study Officials

  • Håvard Furunes, PhD

    Sykehuset Innlandet HF

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Data will be plotted into a database by an independent blinded data manager.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomised controlled multicentre trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 28, 2020

First Posted

November 4, 2020

Study Start

December 28, 2020

Primary Completion

June 1, 2025

Study Completion

June 1, 2025

Last Updated

May 16, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

We have planned to use all the IPD only within the present study group.

Locations